Hyperinsulinemia - A Pipeline Analysis Report

Overview of the drug development for hyperinsulinemia

Hyperinsulinemia is a condition in which abnormally high levels of insulin circulate in the body. Insulin is a hormone produced by the pancreas to maintain the blood sugar levels in the body. Hyperinsulinemia is associated with metabolic syndromes such as hypertension, obesity, dyslipidemia, and glucose intolerance. Hyperinsulinemia is often caused due to insulin resistance, which means, the body does not respond correctly to insulin. This condition can further lead to high blood sugar levels as diabetes progresses, high blood pressure, high cholesterol, and reduced blood fat levels. Hyperinsulinemia is often associated with type 2 diabetes in adults. In neonates, congenital hyperinsulinemia can be observed from birth. Congenital hyperinsulinemia is often caused by mutations in genes that regulate the release of insulin, which is produced by beta cells in the pancreas. The severity of congenital hyperinsulinemia varies widely among affected individuals, even among the members of the same family. According to NIH report in 2018, congenital hyperinsulinemia affects approximately 1 in 50,000 newborns in the US. Consequently, the rising incidences of this condition is expected to boost the drug development for hyperinsulinemia in the next few years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for hyperinsulinemia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hyperinsulinemia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• Crinetics Pharmaceuticals
• Heptares Therapeutics
• Rezolute
• Seneb BioSciences
• Zealand Pharma

Therapeutic assessment of the drug development for hyperinsulinemia by route of administration

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Subcutaneous/Intravenous

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development for hyperinsulinemia by therapeutic modalities

• Small molecule
• Monoclonal antibody
• Biological
• Peptide

According to this pipeline analysis report, most of the molecules currently developed in the drug development for hyperinsulinemia are being developed as small molecules and most of these molecules are chemically manufactured active substances entering the cells easily due to their low molecular weight of less than 900 Daltons.

Key questions answered in the report include

• What are the drug molecules in the various development stages for hyperinsulinemia?
• What are the companies that are currently involved in the development of drug molecules for hyperinsulinemia?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.